BioNTech SE from Mainz has successfully made the leap to the American technology exchange Nasdaq. The company made its debut on the stock exchange and raised 150 million US-dollars.
The Mainz-based biotech company BioNTech SE does not lack in prominent investors. The Bill and Melinda Gates Foundation is now investing $55 million. And the amount can still grow to $100 million.
Once again, the Mainz-based company BioNTech has secured a sum in the hundred-million-euro range. Two thirds of the capital was contributed by new investors.
BioNTech SE announces the start of clinical development for its drug candidate DuoBody PD-L1x4-1BB.
With the help of investors both new and old, the Freiburg-based start-up is taking the next big step in the introduction of its innovative technology for the rapid detection of multi-resistant germs.
The "vaccination against tick bites" of the Norden Vaccines team is among the winners of the Innovation Prize of the Bioregions of Germany 2019.
Rumors have it that BioNTech is preparing for an IPO on the US technology exchange Nasdaq. According to Reuters, the company has entrusted two US banks with the preparations.
CorTec GmbH was again included in this year's list of the most innovative companies in Germany. It had already been honored in 2018.
For his work on cancer immunotherapies, Professor Ugur Sahin, founder and CEO of BioNTech AG, was honored with this year's German Cancer Award.
The EU consortium led by iThera Medical is funded by the European Fast Track to Innovation programme. The aim is to advance the so-called MSOT technology.
Since 2015, BioNTech AG and Sanofi have been partners in the development of cancer therapies. The cooperation is now being extended with an investment of 80 million euros.
Freiburg-based SpinDiag GmbH succeeds in concluding a series A round on 3 million euros. The funds will be used to start clinical validation in Europe.
Berlin-based Omeicos Therapeutics GmbH receives 17 million euros to advance the clinical testing of its substance for the treatment of cardiac arrhythmia.
The peptide-based cancer drug AMC303 from the biotech company amcure GmbH has shown good tolerability in initial clinical studies.
The next GO-Bio Investmentlounge is just around the corner: around 80 participants – among them investors and founding teams – are expected to join the event on 08 - 09 November near Berlin.
The Munich-based medical technology start-up iThera Medical GmbH raised 7 million euros in mid-September. The capital will be used chiefly to finance clinical studies.
BioNTech AG has forged another top-class alliance with a large pharmaceutical company: together with Pfizer, the Mainz-based company plans to develop novel flu vaccines.
After successful funding, the start-up company Purenum has started its work. The aim is to further develop the biocompatible medical adhesive developed in the GO-Bio project mediNik.
The Pro-Detekt research group based at the Life Science Incubator (LSI) in Saxony was able to extend its patent protection for the key PRET-ELISA technology to the USA.
The GO-Bio winners for 2018 have been named: Eight start-up teams took home awards from the biotechnology conference in Berlin. They will each receive funding running into millions of euros from the BMBF.